

Kader Yagiz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10978002/publications.pdf>

Version: 2024-02-01

20
papers

1,164
citations

394421

19
h-index

752698

20
g-index

20
all docs

20
docs citations

20
times ranked

1913
citing authors

#	ARTICLE	IF	CITATIONS
1	HMGB1 Mediates Endogenous TLR2 Activation and Brain Tumor Regression. <i>PLoS Medicine</i> , 2009, 6, e1000010.	8.4	310
2	B Cells Are Critical to T-cell-Mediated Antitumor Immunity Induced by a Combined Immune-Stimulatory/Conditionally Cytotoxic Therapy for Glioblastoma. <i>Neoplasia</i> , 2011, 13, 947-IN23.	5.3	96
3	Release of HMGB1 in Response to Proapoptotic Glioma Killing Strategies: Efficacy and Neurotoxicity. <i>Clinical Cancer Research</i> , 2009, 15, 4401-4414.	7.0	95
4	Gene therapy-mediated delivery of targeted cytotoxins for glioma therapeutics. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 20021-20026.	7.1	88
5	Antiglioma Immunological Memory in Response to Conditional Cytotoxic/Immune-Stimulatory Gene Therapy: Humoral and Cellular Immunity Lead to Tumor Regression. <i>Clinical Cancer Research</i> , 2009, 15, 6113-6127.	7.0	68
6	Gene Therapy and Targeted Toxins for Glioma. <i>Current Gene Therapy</i> , 2011, 11, 155-180.	2.0	66
7	Threonine-120 Phosphorylation Regulated by Phosphoinositide-3-Kinase/Akt and Mammalian Target of Rapamycin Pathway Signaling Limits the Antitumor Activity of Mammalian Sterile 20-Like Kinase 1. <i>Journal of Biological Chemistry</i> , 2012, 287, 23698-23709.	3.4	51
8	Gene Therapy for Brain Cancer: Combination Therapies Provide Enhanced Efficacy and Safety. <i>Current Gene Therapy</i> , 2009, 9, 409-421.	2.0	48
9	Plasmacytoid Dendritic Cells in the Tumor Microenvironment: Immune Targets for Glioma Therapeutics. <i>Neoplasia</i> , 2012, 14, 757-IN26.	5.3	46
10	Gene therapy and virotherapy: novel therapeutic approaches for brain tumors. <i>Discovery Medicine</i> , 2010, 10, 293-304.	0.5	38
11	A Novel Bicistronic High-Capacity Gutless Adenovirus Vector That Drives Constitutive Expression of Herpes Simplex Virus Type 1 Thymidine Kinase and Tet-Inducible Expression of Flt3L for Glioma Therapeutics. <i>Journal of Virology</i> , 2010, 84, 6007-6017.	3.4	37
12	Gene Therapy-Mediated Reprogramming Tumor Infiltrating T Cells Using IL-2 and Inhibiting NF- κ B Signaling Improves the Efficacy of Immunotherapy in a Brain Cancer Model. <i>Neurotherapeutics</i> , 2012, 9, 827-843.	4.4	33
13	Temozolomide Does Not Impair Gene Therapy-Mediated Antitumor Immunity in Syngeneic Brain Tumor Models. <i>Clinical Cancer Research</i> , 2014, 20, 1555-1565.	7.0	32
14	STAT3 and STAT5A are potential therapeutic targets in castration-resistant prostate cancer. <i>Oncotarget</i> , 2017, 8, 85997-86010.	1.8	32
15	Human Flt3L Generates Dendritic Cells from Canine Peripheral Blood Precursors: Implications for a Dog Glioma Clinical Trial. <i>PLoS ONE</i> , 2010, 5, e11074.	2.5	30
16	Protective role of osteopontin in endodontic infection. <i>Immunology</i> , 2010, 129, 105-114.	4.4	24
17	Mapping the STK4/Hippo signaling network in prostate cancer cell. <i>PLoS ONE</i> , 2017, 12, e0184590.	2.5	22
18	Both cell-surface and secreted CSF-1 expressed by tumor cells metastatic to bone can contribute to osteoclast activation. <i>Experimental Cell Research</i> , 2009, 315, 2442-2452.	2.6	20

#	ARTICLE	IF	CITATIONS
19	Toca 511 plus 5-fluorocytosine in combination with lomustine shows chemotoxic and immunotherapeutic activity with no additive toxicity in rodent glioblastoma models. <i>Neuro-Oncology</i> , 2016, 18, 1390-1401.	1.2	19
20	Targeted Toxins for Glioblastoma Multiforme: Pre-Clinical Studies and Clinical Implementation. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2011, 11, 729-738.	1.7	9